Windham Venture Partners Activity

Every public signal F4 has attached to this firm, with sources and cross-entity links.

Types

Time range

3 milestones· JUL 2026 – OCT 2026Show all

Milestone

Clever Care Health Plan, a Windham portfolio company, achieved a 4.5-Star Medicare Advantage rating from CMS for Star Year 2027.

Clever Care Health Plan

Windham Venture Partners | Activity | F4

Windham Venture Partners

globenewswire.comOCT 8, 2026

OCT 8, 2026

Milestone

Neuspera's Integrated Sacral Neuromodulation System (iSNM) to receive same Medicare payment as legacy implantable SNM devices under proposed 2027 CMS rule.

NeuSpera

NeuSpera Windham Venture Partners

prnewswire.comJUL 8, 2026

JUL 8, 2026

Milestone

FORE Biotherapeutics closed an upsized $67.4M Series D-2 extension financing, highlighting recent plixorafenib achievements.

Fore Biotherapeutics

Fore Biotherapeutics Windham Venture Partners

businesswire.comJUL 7, 2026

JUL 7, 2026

News

Managing Partner David Kereiakes joined the AO Foundation Technology Transfer Board to translate surgical innovation into patient impact.

David Kereiakes joined the AO Foundation Technology Transfer Board

Windham Venture Partners

windhamcap.comJUN 15, 2026

JUN 15, 2026

Milestone

PainTEQ launched TRAQ, a next-generation posterior approach to SI joint fusion.

PainTEQ

PainTEQ Windham Venture Partners

prnewswire.comMAY 15, 2026

MAY 15, 2026

Milestone

CVRx announced Humana Medicare Advantage coverage policy for Barostim therapy.

CVRx

CVRx Windham Venture Partners

markets.businessinsider.comMAY 14, 2026

MAY 14, 2026

Team Change

Windham Capital Partners' Managing Partner David Kereiakes joined the AO Foundation Technology Transfer Board to help translate surgical innovation into patient impact.

Windham Venture Partners

Windham Venture PartnersWindham Venture Partners

prnewswire.comMAY 12, 2026

MAY 12, 2026

Milestone

FORE Biotherapeutics received Breakthrough Therapy Designation for Plixorafenib from FDA.

Fore Biotherapeutics

Fore Biotherapeutics Windham Venture Partners

windhamvp.comAPR 1, 2026

APR 1, 2026

Team Change

Dr. Alistair Erskine, Chief Digital Officer and Chief Information Officer of Emory University, appointed as Operating Partner.

Dr. Alistair Erskine appointed Operating Partner

Windham Venture Partners

windhamvp.comJAN 9, 2026

JAN 9, 2026

Team Change

Jason Helgerson, former New York Medicaid Director, appointed as Operating Partner.

Jason Helgerson appointed Operating Partner

Windham Venture Partners

windhamvp.comJAN 9, 2026

JAN 9, 2026

4 milestones· JUN 2025 – OCT 2025Show all

Milestone

Alto Neuroscience announced plans to accelerate development of ALTO-207 in treatment-resistant depression following FDA meeting.

Alton Neuroscience

Alton Neuroscience Windham Venture Partners

windhamvp.comOCT 20, 2025

OCT 20, 2025

Milestone

PainTEQ secured majority growth recapitalization co-led by Signet Healthcare Partners and Windham Capital Partners.

PainTEQ

PainTEQ Windham Venture Partners

windhamvp.comAUG 27, 2025

AUG 27, 2025

Milestone

CVRx announced positive news on outpatient payment for Barostim therapy, improving reimbursement landscape.

CVRx

CVRx Windham Venture Partners

windhamvp.comJUL 16, 2025

JUL 16, 2025

Milestone

Neuspera Medical received FDA approval for its integrated sacral neuromodulation system for urinary urge incontinence.

NeuSpera

NeuSpera Windham Venture Partners

windhamvp.comJUN 18, 2025

JUN 18, 2025

Page 1 of 2